Use of Darunavir-Cobicistat as a Treatment Option for Critically Ill Patients with SARS-CoV-2 Infection

We retrospectively reviewed patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections who were admitted to an intensive care unit in Daegu, South Korea. The outcomes of patients who did (cases) or did not (controls) receive darunavir-cobicistat (800–150 mg) therapy were c...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Eun Jin, Choi, Sun Ha, Park, Jae Seok, Kwon, Yong Shik, Lee, Jaehee, Kim, Yeonjae, Lee, Shin Yup, Choi, Eun Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Yonsei University College of Medicine 2020
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471078/
https://www.ncbi.nlm.nih.gov/pubmed/32882767
http://dx.doi.org/10.3349/ymj.2020.61.9.826

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471078/
https://www.ncbi.nlm.nih.gov/pubmed/32882767
http://dx.doi.org/10.3349/ymj.2020.61.9.826

Ejemplares similares